Breakthrough cancer pain

Current Pain and Headache Reports

Volumn 18, Issue 6, 2014, Pages

  Davies, Andrew N ^a  

^a ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Breakthrough pain; Cancer pain; Episodic pain; Incident pain

Indexed keywords

FENTANYL; FENTANYL CITRATE; OPIATE; MORPHINE; NARCOTIC ANALGESIC AGENT;

ANALGESIA; ARTICLE; BREAKTHROUGH PAIN; CANCER PAIN; CLINICAL FEATURE; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DRUG USE; HUMAN; PALLIATIVE THERAPY; PREVALENCE; TREATMENT PLANNING; COMPLICATION; FEMALE; MALE; META ANALYSIS; MUCOSAL ADMINISTRATION; NEOPLASM; PAIN MEASUREMENT;

ADMINISTRATION, MUCOSAL; ANALGESICS, OPIOID; BREAKTHROUGH PAIN; FEMALE; HUMANS; MALE; MORPHINE; NEOPLASMS; PAIN MEASUREMENT;

EID: 84899696886     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-014-0420-9     Document Type: Article

References (31)

1. Portenoy RK, Hagen NA. Breakthrough pain: definition and management. Oncol Huntingt. 1989;3(8 Suppl):25-9. (Pubitemid 19224897)
2. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273-81. (Pubitemid 20187930)
3. .•• Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331-8. Expert (UK) recommendations on diagnosis and management of breakthrough pain.
4. .• Deandrea S, Corli O, Consonni D, et al. Prevalence of breakthrough cancer pain: a systematic review and pooled analysis of published literature. J Pain SymptomManag. 2014;47:57-76. First systematic review of the prevalence of breakthrough cancer pain in the literature.
5. Portenoy RK. Treatment of temporal variations in chronic cancer pain. Semin Oncol. 1997;5(S16):7-12.
6. Mercadante S, Zagonel V, Breda E, et al. Breakthrough pain in oncology: a longitudinal study. J Pain Symptom Manag. 2010;40:183-90.
7. .•• Davies A, Buchanan A, Zeppetella G, et al. Breakthrough cancer pain: an observational study of 1000 European oncology patients. J Pain Symptom Manag. 2013;46:619-28. Largest study of the clinical features of breakthrough cancer pain in the literature.
8. .• Bedard G, Hawley P, Zhang L, et al. A survey of Canadian cancer patients' perspectives on the characteristics and treatment of breakthrough pain. Support Care Cancer. 2013;21:2557-63.
9. Saini A, Tucci M, Tampellini M, et al. Circadian variation of breakthrough pain in cancer patients. Eur J Pain. 2013;17:264-70.
10. Fine PG, Busch MA. Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manag. 1998;16:179-83. (Pubitemid 28429066)
11. Bruera E, Macmillan K, Kuehn N, Miller MJ. Circadian distribution of extra doses of narcotic analgesics in patients with cancer pain: a preliminary report. Pain. 1992;49:311-4.
12. Citron ML, Kalra JM, Seltzer VL, Chen S, Hoffman M, Walczak MB. Patient-controlled analgesia for cancer pain: a long term study of inpatient and outpatient use. Cancer Investig. 1992;10:335-41.
13. Davies A. Cancer-related Breakthrough Pain. 2nd ed. Oxford: Oxford University Press; 2012.
14. .•• Zeppetella G, Davies A, Rios C, Eijgelshoven I, Jansen JP. A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. J Pain Symptom Manag. 2013. doi:10.1016/j.jpainsymman. 2013.05.020. Most complete and up-to-date network analysis of the efficacy of rescue medication for breakthrough cancer pain in the literature.
15. Vissers D, Stam W, Nolte T, Lenre M, Jansen J. Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer. Curr Med Res Opin. 2010;26:1037-45.
16. Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manag. 2013. doi:10.1016/j.jpainsymman.2012.09.009.
17. Farrar JT, Cleary J, Rauck R, Busch M, Nordbrock E. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998;90:611-6. (Pubitemid 28204805)
18. Coluzzi PH, Schwartzberg L, Conroy Jr JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) andmorphine sulfate immediate release (MSIR). Pain. 2001;91:123-30. (Pubitemid 32274181)
19. Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22:805-11. (Pubitemid 44627444)
20. Slatkin NE, Xie F, Messina J, Segal TJ. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol. 2007;5:327-34. (Pubitemid 350055013)
21. Kress HG, Oronska A, Kaczmarek Z, Kaasa S, Colberg T, Nolte T. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, cross-over trial with a 10-month, open-label extension treatment period. Clin Ther. 2009;31:1177-91.
22. Mercadante S, Radbruch L, Davies A, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25:2805-15.
23. Fallon M, Reale C, Davies A, et al. Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study. J Support Oncol. 2011;9:224-31.
24. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877-85.
25. Portenoy RK, Burton AW, Gabrail N, Taylor D. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain. 2010;151:617-24.
26. Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film(FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21:1308-14.
27. Rauck R, Reynolds L, Geach J, et al. Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. 2012;28:859-70.
28. Mercadante S, Porzio G, Alelli F, Averna L, Ficorella C, Casuccio A. The use of fentanyl buccal tablets for breakthrough pain by using doses proportional to opioid basal regimen in a home care setting. Support Care Cancer. 2013;21:2335-9.
29. Mercadante S, Prestia G, Casuccio A. The use of sublingual fentanyl for breakthrough pain by using doses proportional to opioid basal regimen. Curr Med Res Opin. 2013;29:1527-32. doi:10.1185/03007995.2013.826640.
30. Davies AN, Vriens J, Kennett A, McTaggart M. An observational study of oncology patients' utilisation of breakthrough pain medication. J Pain Symptom Manag. 2008;35:406-11.
31. Davies AN, Zeppetella G, Andersen S, et al.Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;15:756-63.